William Irving is a Professor and Honorary Consultant in virology at Nottingham University and Nottingham University Hospitals Trust. His research interest is in viral hepatitis, particularly HCV infection. He chairs and co-ordinates the Trent HCV Cohort study which has been studying the epidemiology and natural history of HCV infection in a cohort of over 2000 patients since 1991, with support from the Department of Health (DH) and the pharmaceutical industry. The Trent Group has published a number of papers, most recently describing mortality statistics within the cohort, the natural history of severe fibrosis associated with HCV infection, and an extensive analysis of responses to pegylated interferon and ribavirin combination therapy. Professor Irving is Deputy Chair of the DH Advisory Group on Hepatitis, which has produced guidance on the fitness to the practice of HCV-infected health-care workers. He was also a Member of the committee that drafted the DH HCV Strategy for England and Wales.
Biography Updated on 20 August 2008